One Safety Platform for Human and Animal Vigilance Portfolios

How a unified Salesforce-native safety spine lets sponsors run human pharmacovigilance and multivigilance portfolios on one E2B(R3)-aligned architecture.

When multivigilance turns safety architecture into a governance question across human and non-human portfolios

The moment your organisation moves beyond traditional human-drug pharmacovigilance into vaccines, biologics, devices, cosmetics, nutrition, or animal health, “PV architecture” becomes “multivigilance governance.” What began as a single line of business supporting IND and post-marketing safety for human medicines quickly turns into a portfolio: vaccine vigilance linked to public health programmes, biovigilance for cell and gene therapies, device vigilance for combination products, cosmetovigilance and nutrivigilance tied to consumer-facing lines, and veterinary pharmacovigilance for animal health holdings.

On paper, this can look manageable. Many regulatory concepts travel reasonably well: valid cases; seriousness and expectedness assessments; ICSRs; signal management frameworks under EMA GVP Module IX; and risk management planning under ICH E2E and EMA GVP Module V. Privacy obligations under GDPR—especially Article 9’s rules for processing health and other special categories of data (GDPR Article 9 text)—and post-authorisation safety expectations under ICH E2D sit over all of them.

In technology terms, however, most organisations still treat each vigilance line as its own stack. Human PV runs on one safety system integrated with a particular EDC and CTMS. Vaccine vigilance may share some infrastructure but add separate registries or public health interfaces. Device and combo-product safety live in different tools; cosmetovigilance and nutrivigilance rely on complaint systems and consumer channels; veterinary safety uses its own applications. Redaction and anonymisation processes for GDPR Article 9, EMA Policy 0070, and HIPAA often sit outside all of these, in generic document tools or vendor platforms.

For QPPVs, Drug Safety Officers, and heads of Pharmacovigilance, this fragmentation shows up in three ways. First, it complicates ICSR management: ICH E2B(R3) is the technical standard for electronic ICSRs, but internal case models often diverge across portfolios, making E2B(R3) alignment a mapping problem rather than a design principle. Second, it makes audit and inspection readiness fragile: awareness timelines, case changes, and data flows must be reconstructed across multiple systems each time. Third, it weakens privacy governance: GDPR Article 9 and EMA Policy 0070 are implemented through SOPs and training, but actual redaction and anonymisation work happens in sidecar tools with partial audit trails.

The question is no longer whether multivigilance is coming; it is whether your safety architecture can support it without multiplying risk and workload every time a new portfolio is added.

Aligning ICH E2B(R3), GVP Module VI, and privacy frameworks on a unified Salesforce-native safety platform

The governance challenge in multivigilance is not simply volume; it is heterogeneity. Human-drug pharmacovigilance has well-established regulatory anchors: ICH E2A for SUSAR definitions, ICH E2D for post-approval safety data management, ICH E2E for pharmacovigilance planning and risk management, EMA GVP Modules VI, IX, and V for post-authorisation processes, and 21 CFR 312.32 and 21 CFR 314.80 for US clinical and post-marketing reporting. ICSRs for human medicines in the EU must be transmitted to EudraVigilance in ICH E2B(R3) format, as described in EMA’s implementation guidance (EMA E2B(R3) implementation overview and implementation guide PDF).

Non-human lines bring different combinations of expectations and systems. Vaccine vigilance often shares human PV infrastructure but adds programme-level reporting to public health bodies. Biovigilance for cell and gene therapies intersects with advanced therapy frameworks and transplant rules. Device vigilance follows device-specific regulations and reporting pathways. Cosmetovigilance and nutrivigilance rely heavily on national frameworks and consumer-facing channels. Veterinary pharmacovigilance involves separate regulators and data flows but many of the same core disciplines around case validity, seriousness, expectedness, and benefit–risk assessment.

Across all of these, privacy frameworks such as GDPR—especially Article 9’s rules for processing health and other special categories of data (GDPR Article 9 text)—and EMA Policy 0070’s requirements for redaction and anonymisation in public clinical data play a central role. HIPAA governs protected health information in relevant US contexts. The EMA’s external guidance on Policy 0070 (Policy 0070 external guidance) describes in detail how clinical reports must be anonymised before publication, directly relevant to safety narratives and aggregate outputs that may be reused.

In most organisations, these lines of business have evolved on their own stacks. Human PV lives on one safety system, vaccine vigilance on a variant of it, device vigilance on another platform, and animal health on yet another. EDC and CTMS landscapes are similarly fragmented. Redaction and anonymisation processes live in sidecar tools separate from safety. That means QPPVs, Pharmacovigilance leads, and global heads of Safety and Risk Management are responsible for governance across portfolios without a single place where case structures, ICSR quality, audit trails, and privacy controls can be seen and managed together.

Designing one multivigilance case, audit, and privacy model that scales across human and non-human portfolios

Cloudbyz is designed to give sponsors one safety spine that can carry this multivigilance load without sacrificing regulatory precision. Cloudbyz is the only 100% Salesforce-native unified eClinical platform in this space, running Safety, EDC, and CTMS on a shared data, security, and audit model. Cloudbyz Safety sits at the centre of that spine, providing a case object and workflow that are aligned with ICH E2A definitions for SUSARs and ICH E2B(R3) structures for ICSRs. Cloudbyz EDC captures adverse events and related data on CDASH-aligned eCRFs. Cloudbyz CTMS contributes structured trial and programme context—site, country, protocol version, subject status, and milestone history—on the same records.

With that foundation, human pharmacovigilance, vaccine vigilance, biovigilance, device vigilance, cosmetovigilance, nutrivigilance, and veterinary pharmacovigilance can all be configured as portfolios on a single Salesforce-native safety spine. The core case model—patients or animals, reporters, products, indications, reactions, tests, outcomes, MedDRA-coded terms for human and vaccine work, and appropriate taxonomies for other portfolios—remains consistent. Portfolio-specific logic handles seriousness and expectedness criteria, line-specific reporting pathways, and different downstream formats, but cases share the same audit behaviour and quality expectations.

clinRedact AI, part of ClinicalWave.ai, operates within Cloudbyz Safety as an automated PII redaction capability for safety documents. Because it is embedded directly in the workflow, it can enforce GDPR Article 9, EMA Policy 0070, and HIPAA-aligned redaction rules across human and non-human portfolios without moving documents into sidecar tools. ALCOA+-aligned Cloudbyz Audit Trail & e-Signature capabilities track case edits, configuration changes, document generation, and redaction runs as first-class events.

For QPPVs, Drug Safety Officers, Pharmacovigilance leads, and Regulatory Affairs Directors, this unified architecture means ICSR quality metrics, E2B(R3) field completeness, duplicate patterns, and privacy compliance indicators can all be monitored from a single set of dashboards. They can see, for example, whether ICSR rejection rates in EudraVigilance cluster around certain portfolios or geographies, whether E2B(R3) field omissions correlate with specific data sources, and how often safety narratives are redacted and approved per line. Because Safety, EDC, and CTMS share the same Salesforce-native spine, they can also trace issues back to root causes in data capture or trial design, not just patch them at the export layer.

In an environment where portfolios rarely stay within the boundaries of traditional human PV, this kind of unification is increasingly non-negotiable. It turns multivigilance governance from a patchwork of system-specific practices and exception lists into a single, auditable architecture anchored in ICH E2B(R3), GVP Module VI, GDPR Article 9, EMA Policy 0070, and – for US work – 21 CFR 312.32 and 21 CFR 314.80. That is what it looks like when “one safety platform for human and animal vigilance portfolios” is more than a slide—when it is how the work actually runs.

You can create this post directly through the Cloudbyz blog suggestions UI and adapt examples, portfolios, and implementation detail to match your Cloudbyz Safety deployment.